$21 / share would not even cover the breast cancer

$21 / share would not even cover the breast cancer indication. I would say that's not even close. I understand that you want to guess but let's get real, we have a barometer already in IMMU for 21 billion. We have a better drug and a host of other indications that haven't even been accounted for. My guess would be double that.
I know, I know...don't be greedy. But that's a more realistic number for it at this stage. If we partner and wait, it's worth much more.